Wall Street brokerages expect that Recro Pharma Inc (NASDAQ:REPH) will report earnings per share (EPS) of ($0.36) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Recro Pharma’s earnings. The lowest EPS estimate is ($0.83) and the highest is ($0.04). Recro Pharma reported earnings per share of ($0.62) during the same quarter last year, which suggests a positive year over year growth rate of 41.9%. The business is expected to issue its next earnings report on Tuesday, August 6th.

On average, analysts expect that Recro Pharma will report full-year earnings of ($0.54) per share for the current year, with EPS estimates ranging from ($1.90) to $0.12. For the next year, analysts anticipate that the business will post earnings of $0.06 per share, with EPS estimates ranging from ($1.56) to $0.76. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Recro Pharma.

Recro Pharma (NASDAQ:REPH) last released its quarterly earnings data on Friday, May 10th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.79) by $0.69. The business had revenue of $25.07 million during the quarter, compared to analyst estimates of $20.51 million. Recro Pharma had a negative return on equity of 654.93% and a negative net margin of 83.56%.

Several equities analysts recently weighed in on the company. Zacks Investment Research upgraded Recro Pharma from a “hold” rating to a “buy” rating and set a $9.25 price target for the company in a research note on Wednesday, April 24th. ValuEngine lowered Recro Pharma from a “buy” rating to a “hold” rating in a research note on Monday, March 25th. Roth Capital restated a “neutral” rating and issued a $7.50 price target (down previously from $15.00) on shares of Recro Pharma in a research note on Monday, March 25th. Oppenheimer set a $18.00 price target on Recro Pharma and gave the company a “buy” rating in a research note on Wednesday, February 20th. Finally, Janney Montgomery Scott restated a “buy” rating and issued a $13.00 price target on shares of Recro Pharma in a research note on Thursday, January 31st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Recro Pharma has a consensus rating of “Buy” and an average target price of $10.95.

In related news, Director Arnaud Ajdler bought 40,000 shares of the stock in a transaction dated Friday, May 17th. The shares were acquired at an average cost of $9.00 per share, for a total transaction of $360,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Geraldine Henwood sold 144,806 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $8.89, for a total value of $1,287,325.34. Following the transaction, the chief executive officer now owns 342,947 shares in the company, valued at $3,048,798.83. The disclosure for this sale can be found here. Insiders own 20.10% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Meeder Asset Management Inc. boosted its holdings in shares of Recro Pharma by 191.1% during the 1st quarter. Meeder Asset Management Inc. now owns 5,086 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 3,339 shares during the last quarter. Truvestments Capital LLC acquired a new position in Recro Pharma in the first quarter valued at approximately $38,000. Virtu Financial LLC lifted its holdings in Recro Pharma by 27.7% in the first quarter. Virtu Financial LLC now owns 12,875 shares of the specialty pharmaceutical company’s stock valued at $75,000 after acquiring an additional 2,795 shares during the last quarter. State of Wisconsin Investment Board lifted its holdings in Recro Pharma by 29.5% in the first quarter. State of Wisconsin Investment Board now owns 23,700 shares of the specialty pharmaceutical company’s stock valued at $139,000 after acquiring an additional 5,400 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in Recro Pharma by 47.8% in the fourth quarter. Rhumbline Advisers now owns 23,753 shares of the specialty pharmaceutical company’s stock valued at $169,000 after acquiring an additional 7,679 shares during the last quarter. Institutional investors and hedge funds own 56.12% of the company’s stock.

Shares of Recro Pharma stock traded up $0.14 on Tuesday, hitting $9.13. The company’s stock had a trading volume of 203,400 shares, compared to its average volume of 360,620. The company has a quick ratio of 2.08, a current ratio of 3.56 and a debt-to-equity ratio of 4.04. Recro Pharma has a 1 year low of $4.78 and a 1 year high of $13.05. The firm has a market cap of $199.41 million, a PE ratio of -3.67 and a beta of -0.13.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

See Also: Dividend Stocks – Are They Right For You?

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.